Cell Therapy News Volume 25.08 | Mar 25 2024

    By
    lbeveridge
    -
    0
    10








    2024-03-25 | CTN 15.08


    Cell Therapy News by STEMCELL Technologies
    Vol. 15.08 – 25 March, 2024
    TOP STORY

    DNAJB1-PRKACA Fusion Neoantigens Elicit Rare Endogenous T Cell Responses that Potentiate Cell Therapy for Fibrolamellar Carcinoma

    Scientists defined endogenous CD8 T cell responses to a conserved DNAJB1-PRKACA gene fusion in fibrolamellar carcinoma patients and evaluated fusion-specific T cell receptors for use in cellular immunotherapies.
    [Cell Reports Medicine]

    Full ArticleGraphical Abstract
    PUBLICATIONSRanked by the impact factor of the journal

    Engineering Pre-Vascularized 3D Tissue and Rapid Vascular Integration with Host Blood Vessels via Co-Cultured Spheroids-Laden Hydrogel

    Human adipose-derived stem cells and human umbilical vein cells were prepared as spheroids, which were encapsulated in gelatin methacryloyl hydrogels to fabricate a 3D pre-vascularized tissue.
    [Biofabrication]

    Abstract

    Enhanced Bacterial Cancer Therapy Delivering Therapeutic RNA Interference of C-Myc

    The attenuated tumour targeting Salmonella typhimurium SL7207 strain was modified to carry chromosomally integrated shRNA expression cassettes at the xylA locus.
    [Cell & Bioscience]

    Full Article

    Locally Directed Recombinant Adeno-Associated Virus–Mediated IGF-1 Gene Therapy Enhances Osteochondral Repair and Counteracts Early Osteoarthritis In Vivo

    Overexpression of insulin-like growth factor 1 (IGF-1) via recombinant adeno-associated viral vectors would improve osteochondral repair and reduce parameters of early perifocal osteoarthrisis in sheep after six months in vivo.
    [American Journal Of Sports Medicine]

    Abstract

    Human Platelet Lysate Enhances In Vivo Activity of CAR-Vδ2 T Cells by Reducing Cellular Senescence and Apoptosis

    Scientists sought to enhance the in vivo longevity of CAR-Vδ2 T cells by modulating ex vivo manufacturing conditions and selecting an optimal CAR costimulatory domain.
    [Cytotherapy]

    Full Article

    CAR’TCR-T Cells Co-Expressing CD33-CAR and dNPM1-TCR as Superior Dual-Targeting Approach for AML Treatment

    CAR’TCR-T cells, co-expressing a CD33-CAR and a transgenic dNPM1-TCR, revealed increased and prolonged anti-tumor activity in vitro, particularly in case of low target antigen expression.
    [Molecular Therapy Oncology]

    AbstractFull ArticleGraphical Abstract

    Optimization of RNAi Efficiency in PVD Neuron of C. elegans

    In order to optimize the RNAi conditions for PVD neuron, scientists fed the worm strains with E. coli HT115 bacteria expressing dsRNA against mec-3, hpo-30, and tiam-1, whose loss of function were known to show dendrite morphology defects in PVD neuron.
    [PLOS One]

    Full Article
    Sign up to read articles, listen to our podcast, or download free toolkits to help you thrive as a scientist.
    REVIEWS

    Subcutaneous Drug Delivery From Nanoscale Systems

    The authors present key advances in the design of nanoscale drug delivery systems, such as polymer–drug conjugates, liposomes, nanoparticles, micelles, for subcutaneous delivery.
    [Nature Reviews Bioengineering]

    Abstract

    Nanomaterials Boost CAR-T Therapy for Solid Tumors

    Investigators evaluated the use of various nanomaterials in the production of CAR-T cells, genetic modification, and in vivo delivery.
    [Advanced Healthcare Materials]

    Abstract
    INDUSTRY AND POLICY NEWS

    FDA Adcomm Backs J&J’s Carvykti, BMS’s Abecma Early in Multiple Myeloma

    The risks of early death in the trials of Johnson & Johnson, Legend Biotech’s Carvykti, Bristol Myers Squibb, and 2seventyBio’s Abcema were not a significant concern for the FDA’s Oncologic Drugs Advisory Committee, which voted to support the approvals of the CAR-T therapies as earlier lines of treatment for multiple myeloma.
    [BioSpace]

    Press Release

    Cutting-Edge CAR-T Cancer Therapy Is Now Made in India — at One-Tenth the Cost

    A small Indian biotechnology company is producing a home-grown version of a cutting-edge cancer treatment known as CAR T-cell therapy that was pioneered in the United States. A single treatment of NexCAR19, manufactured by Mumbai-based ImmunoACT, costs between US$30,000 and $40,000.
    [Nature News]

    Press Release
    FEATURED EVENT

    AI in Biomedicine

    May 1 – 3, 2024
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    MSc/PhD Position – Cell Stress and Inflammation

    University of Manitoba – Winnipeg City, Manitoba, Canada

    Laboratory Scientist – Cell Therapy Research

    University of Colorado – Aurora, Colorado, United States

    Postdoctoral Research Associate – Biomaterial-Cell Interactions

    University of Sydney – Sydney, Australia

    Department Chair – Cell Biology and Human Anatomy

    UC Davis – Davis, California, United States

    Medical Technologist – Clinical Cell Therapy Lab

    BC Provincial Health Services Authority – Vancouver, British Columbia, Canada

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2